Noble Financial Keeps 'Buy' Rating on Cynapsus (CYNA) as APL-130277 Receives FDA Fast Track Designation

Noble Financial affirms Cynapsus Therapeutics (Nasdaq: CYNA) with a Buy rating and $50 price target after the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for APL-130277, a product candidate for the treatment of OFF episodes in patients with Parkinson’s disease (PD).

Analyst Nathan Cali noted the following on Monday:

• Importance of Fast Track Designation. Intends to expedite the approval process while granting invaluable access with the FDA; guidance is meant to closely track and aide ongoing clinical trials for a drug, submissions allowed on a rolling basis for FDA review to help ensure trial fluidity for a potential pathway to success; could lead to shorter review time
• Requirements for Fast Track Validate APL-130277 Clinical Program; obtaining Fast Track requires demonstration of either superior efficacy, avoiding serious side effects, decreasing toxicity or ability to address emerging anticipated public health need
• Price Target $50; Bullish on upcoming milestones. We estimate that the current cash balance of $55.1 million is sufficient to extend operations near 2018 and potential commercialization of APL-130277; data for APL-130277, Phase III efficacy trial expected in Q4-2016; possible NDA submission to take place in 1H-2017.

For an analyst ratings summary and ratings history on Cynapsus click here. For more ratings news on Cynapsus click here.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Jefferies Downgrades Enphase Energy (ENPH) to Hold, 'Still Muddling Through'
• Gain Therapeutics (GANX) Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287